Cite
HARVARD Citation
Casadei-Gardini, A. et al. (2023). Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. European journal of cancer. pp. 9-20. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Casadei-Gardini, A. et al. (2023). Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. European journal of cancer. pp. 9-20. [Online].